[1] YI K K, ZHAN Q, WANG Q X, et al. PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2[J]. Neuro-oncology, 2021, 23(3): 387-399. DOI: 10.1093/neuonc/noaa255.
[2] ZHANG R, SONG Q, LIN X,et al. GSDMA at the crossroads between pyroptosis and tumor immune evasion in glioma[J].Biochem Biophys Res Commun,2023,686:149181. DOI:10.1016/j.bbrc.2023.149181.
[3] MARTINON F, BURNS K, TSCHOPP J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta[J]. Mol Cell, 2002, 10(2): 417-426. DOI: 10.1016/s1097-2765(02)00599-3.
[4] LIU S W, SONG W J, MA G K, et al. Pyroptosis and its role in cancer[J]. World J Clin Cases, 2023, 11(11): 2386-2395. DOI: 10.12998/wjcc.v11.i11.2386.
[5] SUNDARAM B, KANNEGANTI T D. Advances in understanding activation and function of the NLRC4 inflammasome[J]. Int J Mol Sci, 2021, 22(3): 1048. DOI: 10.3390/ijms22031048.
[6] 王文连,林欣,胡俊锋.炎性小体在肺部疾病中的作用[J].中国呼吸与危重监护杂志, 2019,18(4): 404-408. DOI: 10.7507/1671-6205.201805056.
[7] 王变丽,王天怡,张露丹,等.炎性小体及细胞焦亡在肠道稳态中的研究进展[J]. 中国免疫学杂志, 2023, 39(6): 1337-1341. DOI: 10.3969/j.issn.1000-484X.2023.06.046.
[8] 耿晋,朱永杰,耿蕴琦,等.炎性小体及其与结直肠癌关系的研究进展[J].军事医学, 2018, 42(6): 471-475. DOI:10.7644/j.issn.1674-9960.2018.06.016.
[9] CHEW Z H, CUI J Z, SACHAPHIBULKIJ K, et al. Macrophage IL-1β contributes to tumorigenesis through paracrine AIM2 inflammasome activation in the tumor microenvironment[J]. Front Immunol, 2023, 14: 1211730. DOI: 10.3389/fimmu.2023.1211730.
[10] BURDETTE B E, ESPARZA A N, ZHU H,et al. Gasdermin D in pyroptosis[J]. Acta Pharm Sin B, 2021;11(9):2768-2782. DOI:10.1016/j.apsb.2021.02.006
[11] CHRISTGEN S, PLACE D E, KANNEGANTI T D. Toward targeting inflammasomes: insights into their regulation and activation[J]. Cell Res, 2020, 30(4): 315-327. DOI: 10.1038/s41422-020-0295-8.
[12] ROSS C, CHAN A H, VON PEIN J B, et al. Inflammatory caspases: toward a unified model for caspase activation by inflammasomes[J]. Annu Rev Immunol, 2022, 40: 249-269. DOI: 10.1146/annurev-immunol-101220-030653.
[13] CHAUHAN D, VANDE WALLE L, LAMKANFI M. Therapeutic modulation of inflammasome pathways[J]. Immunol Rev, 2020, 297(1): 123-138. DOI: 10.1111/imr.12908.
[14] SHI J J, ZHAO Y, WANG K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death[J]. Nature, 2015, 526(7575): 660-665. DOI: 10.1038/nature15514.
[15] TAPIA-ABELLÁN A, ANGOSTO-BAZARRA D, ALARCÓN-VILA C, et al. Sensing low intracellular potassium by NLRP3 results in a stable open structure that promotes inflammasome activation[J]. Sci Adv, 2021, 7(38): eabf4468. DOI: 10.1126/sciadv.abf4468.
[16] PENG L C, TIAN H L, LU Y, et al. Chicken cathelicidin-2 promotes NLRP3 inflammasome activation in macrophages[J]. Vet Res, 2022, 53(1): 69. DOI: 10.1186/s13567-022-01083-4.
[17] MURAKAMI T, OCKINGER J, YU J J, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome[J]. Proc Natl Acad Sci USA, 2012, 109(28): 11282-11287. DOI: 10.1073/pnas.1117765109.
[18] LIU Q Y, WANG D D, YANG X D, et al. The mechanosensitive ion channel PIEZO1 in intestinal epithelial cells mediates inflammation through the NOD-like receptor 3 pathway in Crohn’s disease[J]. Inflamm Bowel Dis, 2023, 29(1): 103-115. DOI: 10.1093/ibd/izac152.
[19] ZHANG Z, XIE S J, QIAN J, et al. Targeting macrophagic PIM-1 alleviates osteoarthritis by inhibiting NLRP3 inflammasome activation via suppressing mitochondrial ROS/Cl- efflux signaling pathway[J]. J Transl Med, 2023, 21(1): 452. DOI: 10.1186/s12967-023-04313-1.
[20] GREEN J P, YU S, MARTÍN-SÁNCHEZ F, et al. Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming[J]. Proc Natl Acad Sci USA, 2018, 115(40): E9371-E9380. DOI: 10.1073/pnas.1812744115.
[21] CHEN F, FENG L, ZHENG Y L, et al. 2, 2', 4, 4'-tetrabromodiphenyl ether(BDE-47)induces mitochondrial dysfunction and related liver injury via eliciting miR-34a-5p-mediated mitophagy impairment[J]. Environ Pollut, 2020, 258: 113693. DOI: 10.1016/j.envpol.2019.113693.
[22] AN C, SUN F, LIU C, et al. IQGAP1 promotes mitochondrial damage and activation of the mtDNA sensor cGAS-STING pathway to induce endothelial cell pyroptosis leading to atherosclerosis[J]. Int Immunopharmacol, 2023, 123: 110795. DOI: 10.1016/j.intimp.2023.110795.
[23] YANG B W, WANG Y T, FANG C Y, et al. Polybrominated diphenyl ether quinone exposure leads to ROS-driven lysosomal damage, mitochondrial dysfunction and NLRP3 inflammasome activation[J]. Environ Pollut, 2022, 311: 119846. DOI: 10.1016/j.envpol.2022.119846.
[24] HOU Y T, HE H B, MA M, et al. Apilimod activates the NLRP3 inflammasome through lysosome-mediated mitochondrial damage[J]. Front Immunol, 2023, 14: 1128700. DOI: 10.3389/fimmu.2023.1128700.
[25] NEUWIRT E, MAGNANI G, C'IKOVI T, et al. Tyrosine kinase inhibitors can activate the NLRP3 inflammasome in myeloid cells through lysosomal damage and cell lysis[J]. Sci Signal, 2023, 16(768): eabh1083. DOI: 10.1126/scisignal.abh1083.
[26] WANG W Q, CHANG R, WANG Y, et al. Mitophagy-dependent mitochondrial ROS mediates 2, 5-hexanedione-induced NLRP3 inflammasome activation in BV2 microglia[J]. Neurotoxicology, 2023, 99: 50-58. DOI: 10.1016/j.neuro.2023.09.008.
[27] GAI Y, BAI C, ZHANG W, et al. Nootkatone attenuates airway inflammation in asthmatic mice through repressing ROS-induced NLRP3 inflammasome activation[J]. Biochem Cell Biol, 2023, 101(6): 513-522. DOI: 10.1139/bcb-2023-0009.
[28] SU W J, LI J M, ZHANG T, et al. Microglial NLRP3 inflammasome activation mediates diabetes-induced depression-like behavior via triggering neuroinflammation[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2023, 126: 110796. DOI: 10.1016/j.pnpbp.2023.110796.
[29] ROSA C P, BELO T C A, SANTOS N C M, et al. Reactive oxygen species trigger inflammasome activation after intracellular microbial interaction[J]. Life Sci, 2023, 331: 122076. DOI: 10.1016/j.lfs.2023.122076.
[30] TURTON K, PARKS H J, ZARODKIEWICZ P, et al. The Achromobacter type 3 secretion system drives pyroptosis and immunopathology via independent activation of NLRC4 and NLRP3 inflammasomes[J]. Cell Rep, 2023, 42(8): 113012. DOI: 10.1016/j.celrep.2023.113012.
[31] KOIZUMI Y, TOMA C, HIGA N, et al. Inflammasome activation via intracellular NLRs triggered by bacterial infection[J]. Cell Microbiol, 2012, 14(2): 149-154. DOI: 10.1111/j.1462-5822.2011.01707.x.
[32] TIBBLE R, YONEMITSU M A, MITCHELL P S. Stalled but not forgotten: bacterial exotoxins inhibit translation to activate NLRP1[J]. J Exp Med, 2023, 220(10): e20231160. DOI: 10.1084/jem.20231160.
[33] ZHENG D P, KERN L, ELINAV E. The NLRP6 inflammasome[J]. Immunology, 2021, 162(3): 281-289. DOI: 10.1111/imm.13293.
[34] ZHOU Y, SHAH S Z, YANG L F, et al. Virulent mycobacterium bovis Beijing strain activates the NLRP7 inflammasome in THP-1 macrophages[J]. PLoS One, 2016, 11(4): e0152853. DOI: 10.1371/journal.pone.0152853.
[35] JING X, YUN Y H, JI X, et al. Pyroptosis and inflammasome-related genes- NLRP3, NLRC4 and NLRP7 polymorphisms were associated with risk of lung cancer[J]. Pharmgenomics Pers Med, 2023, 16: 795-804. DOI: 10.2147/PGPM.S424326.
[36] CASILI G, SCUDERI S A, LANZA M, et al. Therapeutic potential of BAY-117082, a selective NLRP3 inflammasome inhibitor, on metastatic evolution in human oral squamous cell carcinoma(OSCC)[J]. Cancers, 2023, 15(10): 2796. DOI: 10.3390/cancers15102796.
[37] LI W J, ZHAO X B, ZHANG R J, et al. Silencing of NLRP3 sensitizes chemoresistant ovarian cancer cells to cisplatin[J]. Mediators Inflamm, 2023, 2023: 7700673. DOI: 10.1155/2023/7700673.
[38] LIU H D, LI W, CHEN Z R, et al. Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model[J]. Neurochem Res, 2013, 38(10): 2072-2083. DOI: 10.1007/s11064-013-1115-z.
[39] 樊明德,张源,苗保旺,等.Nod样受体热蛋白结构域相关蛋白3在人脑胶质瘤中的表达[J].山东大学学报(医学版), 2013, 51(4): 51-54. DOI: 10.6040/j.issn.1671-7554.2013.04.012.
[40] HAN S Y, ZHANG Z M, MA W B, et al. Nucleotide-binding oligomerization domain(NOD)-like receptor subfamily C(NLRC)as a prognostic biomarker for glioblastoma multiforme linked to tumor microenvironment: a bioinformatics, immunohistochemistry, and machine learning-based study[J]. J Inflamm Res, 2023, 16: 523-537. DOI: 10.2147/JIR.S397305.
[41] LIM J, KIM M J, PARK Y, et al. Upregulation of the NLRC4 inflammasome contributes to poor prognosis in glioma patients[J]. Sci Rep, 2019, 9(1): 7895. DOI: 10.1038/s41598-019-44261-9.
[42] ZHANG L, JIAO C, LIU L J, et al. NLRC5: a potential target for central nervous system disorders[J]. Front Immunol, 2021, 12: 704989. DOI: 10.3389/fimmu.2021.704989.
[43] VIJAYAN S, SIDIQ T, YOUSUF S, et al. Class I transactivator, NLRC5: a central player in the MHC class I pathway and cancer immune surveillance[J]. Immunogenetics, 2019,71(3):273-282.DOI:10.1007/s00251-019-01106-z.
[44] YIN X F, ZHANG Q, CHEN Z Y, et al. NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN/AKT signaling pathway[J]. Int J Oncol, 2018, 53(3): 973-986. DOI: 10.3892/ijo.2018.4480.
[45] ZHU C, ZOU C Y, GUAN G F, et al. Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma[J]. Oncoimmunology, 2019, 8(9): e1621677. DOI: 10.1080/2162402X.2019.1621677.
[46] 殷小凤.NLRP3在人胶质瘤中的表达及其对胶质瘤细胞生物学行为的作用研究[D].广州:南方医科大学, 2017
[47] BELLUT M, PAPP L, BIEBER M, et al. NLPR3 inflammasome inhibition alleviates hypoxic endothelial cell death in vitro and protects blood-brain barrier integrity in murine stroke[J]. Cell Death Dis, 2021, 13(1): 20. DOI: 10.1038/s41419-021-04379-z.
[48] XUE L, LU B, GAO B, et al. NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-κB p65 signals[J].Oncol Res,2019;27(5):557-564. DOI:10.3727/096504018X15264647024196.
[49] XUE L P, LU B, GAO B B, et al. NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-κB p65 signals[J]. Oncol Res, 2019, 27(5): 557-564. DOI: 10.3727/096504018X15264647024196.
[50] XIE K, ZHOU D M, FANG C, et al. Inhibition of NF-κB activation by BAY 11-7821 suppresses the proliferation and inflammation of glioma cells through inducing autophagy[J]. Transl Cancer Res TCR, 2022, 11(2): 403-413. DOI: 10.21037/tcr-21-2914.
[51] ZONG Z Q, SONG Y C, XUE Y X, et al. Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway[J]. J Cell Mol Med, 2019, 23(8): 5048-5062. DOI: 10.1111/jcmm.14362.
[52] WANG H B, XU G X, HUANG Z J, et al. LRP6 targeting suppresses gastric tumorigenesis via P14ARF-Mdm2-p53-dependent cellular senescence[J]. Oncotarget, 2017, 8(67): 111597-111607. DOI: 10.18632/oncotarget.22876.
[53] YU Y H, CAO F, XIONG Y Q, et al. SP1 transcriptionally activates NLRP6 inflammasome and induces immune evasion and radioresistance in glioma cells[J]. Int Immunopharmacol, 2021, 98: 107858. DOI: 10.1016/j.intimp.2021.107858.
[54] WAN S C, ZHANG G H, LIU R C, et al. Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment[J]. Cell Commun Signal, 2023, 21(1): 115. DOI: 10.1186/s12964-023-01108-1.
[55] TANG N, ZHU Y, YU J. Xihuang pill facilitates glioma cell pyroptosis via the POU4F1/STAT3 axis[J]. Funct Integr Genomics,2023;23(4):334. DOI:10.1007/s10142-023-01263-1.
[56] ZHAO X, CHEN C, HAN W, et al. EEBR induces Caspase-1-dependent pyroptosis through the NF-κB/NLRP3 signalling cascade in non-small cell lung cancer[J].J Cell Mol Med,2024;28(3):e18094. DOI:10.1111/jcmm.18094.
[57] 陈健,郭志娟,裴美娟,等.HIF-1α对人脑胶质瘤SHG44细胞恶性度的影响及其机制[J].武警医学, 2022, 33(6): 484-488. DOI: 10.3969/j.issn.1004-3594.2022.06.007.
[58] FENG X Q, CHEN Y H, LIU X Y, et al. Construction and verification of a novel pyroptosis-related lncRNA signature associated with immune landscape in gliomas[J]. J Oncol, 2022, 2022: 7043431. DOI: 10.1155/2022/7043431.
[59] YANG S, XIE C, GUO T, et al. Simvastatin inhibits tumor growth and migration by mediating caspase-1-dependent pyroptosis in glioblastoma multiforme[J].World Neurosurg,2022;165:e12-e21. DOI:10.1016/j.wneu.2022.03.089
[60] 杜洋,邱鹏程,王媛媛,等.海星皂苷CN-3激活NLRP3/Caspase-1/GSDMD信号通路诱导胶质瘤细胞焦亡的作用[J].环球中医药, 2022, 15(11): 2022-2029. DOI: 10.3969/j.issn.1674-1749.2022.11.006.
[61] WU Y S, CHANG J, GE J J, et al. Isobavachalcone’s alleviation of pyroptosis contributes to enhanced apoptosis in glioblastoma: possible involvement of NLRP3[J]. Mol Neurobiol, 2022, 59(11): 6934-6955. DOI: 10.1007/s12035-022-03010-2.
[62] LIANG Q Y, WU J Q, ZHAO X, et al. Establishment of tumor inflammasome clusters with distinct immunogenomic landscape aids immunotherapy[J]. Theranostics, 2021, 11(20): 9884-9903. DOI: 10.7150/thno.63202.
[63] LI Z, FU W J, CHEN X Q, et al. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization[J]. J Exp Clin Cancer Res, 2022, 41(1): 74. DOI: 10.1186/s13046-022-02291-8.
[64] KIM S M, JEON Y, JANG J Y, et al. NR1D1 deficiency in the tumor microenvironment promotes lung tumor development by activating the NLRP3 inflammasome[J]. Cell Death Discov, 2023, 9(1): 278. DOI: 10.1038/s41420-023-01554-3.
[65] DALEY D, MANI V R, MOHAN N, et al. NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma[J].J Exp Med, 2017;214(6):1711-1724. DOI:10.1084/jem.20161707.
[66] TENGESDAL I W, MENON D R, OSBORNE D G, et al. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion[J]. Proc Natl Acad Sci USA, 2021;118(10):e2000915118. DOI:10.1073/pnas.2000915118.
[67] CHEN Z, GIOTTI B, KALUZOVA M, et al. A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression[J].J Clin Invest, 2023;133(22):e163802. DOI:10.1172/JCI163802.
[68] GELFO V, ROMANIELLO D, MAZZESCHI M, et al. Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies[J].Int J Mol Sci, 2020;21(17):6009. DOI:10.3390/ijms21176009.
[69] LIU J H, GAO L, ZHU X N, et al. Gasdermin D is a novel prognostic biomarker and relates to TMZ response in glioblastoma[J]. Cancers, 2021, 13(22): 5620. DOI: 10.3390/cancers13225620.
[70] TONG L, XIE C C, WEI Y F, et al. Antitumor effects of berberine on gliomas via inactivation of caspase-1-mediated IL-1β and IL-18 release[J]. Front Oncol, 2019, 9: 364. DOI: 10.3389/fonc.2019.00364.
[71] SHANG S, WANG L L, ZHANG Y L, et al. The beta-hydroxybutyrate suppresses the migration of glioma cells by inhibition of NLRP3 inflammasome[J]. Cell Mol Neurobiol, 2018, 38(8): 1479-1489. DOI: 10.1007/s10571-018-0617-2.
[72] HONDA S, SADATOMI D, YAMAMURA Y, et al. WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3[J]. Cancer Sci, 2017, 108(3): 520-527. DOI: 10.1111/cas.13154.
[73] DOS SANTOS DC, RAFIQUE J, SABA S, et al. IP-Se-06, a selenylated imidazo[1, 2- a] pyridine, modulates intracellular redox state and causes akt/mTOR/HIF-1 α and MAPK signaling inhibition, promoting antiproliferative effect and apoptosis in glioblastoma cells[J]. Oxid Med Cell Longev, 2022, 2022: 3710449. DOI: 10.1155/2022/3710449.
[74] CELESTI F, GATTA A, SHALLAK M, et al. Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA[J]. Front Immunol, 2023, 14: 1133177. DOI: 10.3389/fimmu.2023.1133177. (
